Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Back

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Plymouth London Oxford Leicester Leeds Liverpool Glasgow

Medical Conditions

Lymphoma
Hodgkin Disease

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2022 Jan 2026

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion

Intervention Arm Group : Favezelimab/Pembrolizumab;

Intervention Type : DRUG
Intervention Description : IV infusion

Intervention Arm Group : Chemotherapy (Bendamustine or Gemcitabine);

Intervention Type : DRUG
Intervention Description : IV infusion

Intervention Arm Group : Chemotherapy (Bendamustine or Gemcitabine);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Derriford Hospital ( Site 2107)
    Plymouth
    Devon
    Pl6 8DH
  • St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 2105)
    London
    London, City Of
    EC1A 7BE
  • GenesisCare - Oxford ( Site 2104)
    Oxford
    Oxfordshire
    OX4 6LB
  • Leicester Royal Infirmary ( Site 2100)
    Leicester
    LE1 5WW
  • St James's University Hospital ( Site 2109)
    Leeds
    LS9 7TF
  • Clatterbridge Cancer Centre - Liverpool-Heamatology ( Site 2108)
    Liverpool
    L7 8YA
  • The Beatson West of Scotland Cancer Centre ( Site 2110)
    Glasgow
    Glasgow City
    G12 0YN


The study is sponsored by Merck Sharp & Dohme LLC



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05508867
Last updated 29 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top